Product Description: Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis[1][2].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Shirley M, et al. Secukinumab: A Review in Psoriatic Arthritis. Drugs. 2016;76(11):1135-1145./[2]Reich K, et al. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. Br J Dermatol. 2020;182(2):304-315./[3]Elain G, et al. The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes. Glia. 2014;62(5):725-735.
CAS Number: 1229022-83-6
Molecular Weight: N/A
Compound Purity: 99.20
Research Area: Inflammation/Immunology; Cancer
Solubility: H2O
Target: Interleukin Related
English
Deutsch
